Abstract
BackgroundSubcutaneous (sc) interferon (IFN) β-1a reduces relapse rates and delays disability progression in patients with MS. We examined the association of the year 1 Magnetic Resonance Imaging in MS (MAGNIMS) score with long-term clinical disease activity (CDA) -free status and confirmed disability progression in patients treated with sc IFN β-1a in PRISMS. MethodsPatients treated with sc IFN β-1a three-times-weekly (22 or 44 μg; pooled data) were classified by MAGNIMS score (0, n = 129; 1, n = 108; 2, n = 130) at year 1. Hazard ratios (HR; 95% confidence intervals [CI]) for risk of CDA and confirmed Expanded Disability Status Score (EDSS) progression were calculated by MAGNIMS score for up to 15 years of follow-up. ResultsThe risk of CDA was higher with a year 1 MAGNIMS score of 1 versus 0 (HR 1.82 [1.38–2.41]), 2 versus 0 (2.63 [2.01–3.45]) and 2 versus 1 (1.45 [1.11–1.89], all p < 0.0001). The same outcome was observed with the risk of confirmed EDSS progression (1 versus 0: 1.93 [1.23–3.02]; 2 versus 0: 2.95 [1.95–4.46]; 2 versus 1: 1.53 [1.05–2.23]; all p < 0.0001). ConclusionIn PRISMS, MAGNIMS score at Year 1 predicted risk of CDA and confirmed disability progression in sc IFN β-1a-treated patients over up to 15 years.PRISMS-15 clinicaltrial.gov identifier: NCT01034644
Highlights
Interferon β (IFN β) is a well-established first-line treatment for relapsing-remitting (RR) MS, the most common form of MS (Nose worthy et al, 2000)
We examined the association of the year 1 Magnetic Resonance Imaging in MS (MAGNIMS) score with long-term clinical disease activity (CDA) -free status and confirmed disability progression in patients treated with sc IFN β-1a in PRISMS
Using a MAGNIMS score of 0 as a reference, the risk of having a CDA event was significantly higher in patients with MAGNIMS scores of 1 (HR 1.82 [95% CI 1.38–2.41]; p < 0.0001]) and 2 (HR 2.63 [95% CI 2.01–3.45]; p < 0.0001; Table 3)
Summary
Interferon β (IFN β) is a well-established first-line treatment for relapsing-remitting (RR) MS, the most common form of MS (Nose worthy et al, 2000). Sub-optimal patient response to first-line therapies predicts greater risk of relapse and disability progression (Freedman et al, 2017). Patients were classified after 1 year of treatment with IFN β for the risk of disease progression according to the occurrence of relapses (0 to ≥2), and new and enlarging T2 lesions (
Sign-in/Register to view highlights & summary 
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call